Breast cancer
Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?

Tracy (72 years old)

Tracy, 72 years old former actress, enjoys sitting by the fire in her cosy living room, tracing old script notes with a wistful smile.

She was diagnosed with metastatic breast cancer 3 years ago, after she had been treated for early HR+ HER2- breast cancer 12 years ago.

Assessment summary:

  • Postmenopausal
  • No family history of breast cancer
  • ECOG PS: 0
  • Medical history:
    • HR+ HER2- breast cancer T2N0M0 12 years ago. Treated with breast conserving surgery, radiation therapy and letrozole for 5 years
    • Diagnosis metastatic disease 3 years ago (bones, liver). Biopsy of liver metastasis: breast cancer, NST, ER 90%, PgR 60%, HER2 IHC 1+, G2. Treatment with abemaciclib + anastrozole was started
  • Tumour regression in control imaging
  • Most recent CT scan of chest and abdomen and bone scan:
    • Stable multiple bone metastases
    • Progression of 2 liver metastases
  • Haematology and biochemistry: all values normal
  • Somatic PIK3CA mutation status: wild type
  • Somatic ESR1 mutation status (on liquid biopsy): wild type
  • Germline BRCA mutation status: BRCA1 mutation

Which option would you choose for this patient?